ORION CORPORATION     STOCK EXCHANGE RELEASE   26 OCTOBER 2017 at 18.45 P.M. EEST

Composition of the Nomination Committee of Orion Corporation

The Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:

• Kari Jussi Aho
• Erkki Etola
• Petteri Karttunen
• Matti Kavetvuo
• Timo Maasilta
• Timo Ritakallio
• Heikki Westerlund
• Jukka Ylppö

Matti Kavetvuo was elected Chairman of the Committee.  






The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board.






The essentials of the working order of the Nomination Committee and a description of the election process of its members are provided at
http://www.orion.fi/en/Orion-group/corporate-governance/board-of-directors/board-committees/
, a page in the Corporate Governance section of the Orion Group internet website.

  


Orion Corporation

                                                                       


Contact person:


Timo Lappalainen, President and CEO


tel. +358 10 426 3692

Publisher:


Orion Corporation


Communications


Orionintie 1A, FI-02200 Espoo, Finland


Homepage:
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.